CN114044734A - Abietane diterpene and preparation method and application thereof - Google Patents
Abietane diterpene and preparation method and application thereof Download PDFInfo
- Publication number
- CN114044734A CN114044734A CN202111050049.4A CN202111050049A CN114044734A CN 114044734 A CN114044734 A CN 114044734A CN 202111050049 A CN202111050049 A CN 202111050049A CN 114044734 A CN114044734 A CN 114044734A
- Authority
- CN
- China
- Prior art keywords
- petroleum ether
- diol
- dimethyl
- octahydro
- fractions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C35/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07C35/22—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system
- C07C35/37—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system with a hydroxy group on a condensed system having three rings
- C07C35/42—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system with a hydroxy group on a condensed system having three rings derived from the phenanthrene skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/22—Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
- C07C2603/26—Phenanthrenes; Hydrogenated phenanthrenes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The invention relates to the technical field of separation and purification of schizonepeta bracteata, and discloses abietane diterpene and a preparation method and application thereof. The invention discloses a compound 1,2,3,4,4a,9,10,10 a-octahydro-7-isoproyl-2, 4 a-dimethyl-1-methylenetetrahydrocene-2, 9-diol (piperidine D) for the first time, and the compound is subjected to in vitro anti-inflammatory and antibacterial pharmacodynamic experiments, and the experiments show that the compound has stronger inhibition effect on RAW 264.7 cells, staphylococcus aureus and escherichia coli, so that the compound can be used for preparing anti-inflammatory and antibacterial drugs or/and health-care products for preventing and treating inflammation and inhibiting bacteria.
Description
Technical Field
The invention relates to the technical field of separation and purification of schizonepeta bracteata, and discloses abietane diterpene and a preparation method and application thereof, wherein the abietane diterpene is short for 1,2,3,4,4a,9,10,10 a-octahydro-7-isoprop-2, 4 a-dimethyl-1-methylenetetrahydronaphthalene-2, 9-diol (nepetabutyrate D).
Background
Nepeta bracteata Benth is a Nepeta plant of Labiatae Nepeta genus Nepeta, mainly distributed in countries such as Pakistan, Nepal, Iran and the like, is named as 'ancestral', is commonly called hyssop, has wide clinical application and is mainly imported. The whole herbs are used as the medicine, have slight faint scent, light taste and slight dampness, enter lung and liver channels, have the functions of relieving cough and asthma, clearing heat and promoting diuresis, and are clinically used for treating symptoms such as tracheitis, cough and asthma, cold and fever, dysuria and the like. In addition, the schizonepeta cataria has the characteristics of easy source, low cost, reliable clinical treatment effect, small toxic and side effects and the like. So far, the emphasis on the research of the schizonepeta bracteata and the basic theoretical research are not abundant, and modern pharmacology shows that the extractive has remarkable anti-inflammatory and antibacterial activities, but the related research on chemical components is not carried out, and the schizonepeta bracteata is probably a good species for treating respiratory diseases, so that the schizonepeta bracteata is concerned by people in recent years.
The medicinal effect of the schizonepeta cataria is mainly derived from terpenoids in the schizonepeta cataria, including monoterpenes and diterpenoids, wherein diterpenoids as the main components have better anti-inflammatory and bacteriostatic activities, so that the diterpenoid monomeric compounds of the schizonepeta cataria are developed and utilized, the potential medicinal value of the monomeric compounds of the schizonepeta cataria is further excavated, and the structure and the physicochemical properties of the monomeric compounds of the schizonepeta cataria are determined and characterized, thereby having important significance for developing and utilizing the schizonepeta cataria.
Disclosure of Invention
The invention provides 1,2,3,4,4a,9,10,10 a-octahydroph-7-isoproyl-2, 4 a-dimethyl-1-methylenetetrahydronaphthalene-2, 9-diol (piperidine D) and a preparation method and application thereof, overcomes the defects of the prior art, and discloses 1,2,3,4,4a,9,10,10 a-octahydroph-7-isoproyl-2, 4 a-di-1-methylenetetrahydronaphthalene-2, 9-diol (piperidine D) for the first time and application thereof in preparing anti-inflammation and bacteriostatic medicaments or/and preparing anti-inflammation and antibacterial medicaments or/and preparing health-care products for preventing and inhibiting inflammation and bacteria.
One of the technical schemes of the invention is realized by the following measures: 1,2,3,4,4a,9,10,10a-octah hydro-7-isoproyl-2, 4 a-dimethyl-1-methyenenaphthalene-2, 9-diol (neopetanate D) with chemical structural formula
The following is a further optimization or/and improvement of one of the above-mentioned technical solutions of the invention:
the preparation method comprises the following steps: crushing the schizonepeta bracteata, adding ethanol, soaking for 3-4 hours at room temperature, heating and refluxing for 3 times at 50-60 ℃, extracting for 1-3 hours each time, combining the refluxing extracting solutions each time, and recovering and concentrating under reduced pressure to obtain a schizonepeta bracteatum total extract; secondly, dispersing the schizonepeta tenuifolia total extract by using water, and sequentially extracting by using petroleum ether and dichloromethane to obtain a petroleum ether part and a dichloromethane part; and step three, performing gradient elution and separation on the extract at the petroleum ether part by using a silica gel column chromatography to obtain 8 fractions, wherein the gradient eluent of the silica gel column chromatography comprises petroleum ether and ethyl acetate, and the volume ratio of the petroleum ether to the ethyl acetate is 1:0, 100:1 and 50: 1. 25:1, 8:1, 5:1, 1: 0; and fourthly, performing gradient elution separation on the 7 th fraction in the obtained 8 fractions by using a silica gel column chromatography to obtain 5 fractions, wherein the gradient eluent of the silica gel column chromatography comprises petroleum ether and ethyl acetate, and the volume ratio of the petroleum ether to the ethyl acetate is 15:1, 5:1 and 3: 1. 1:1, 0: 1; and fifthly, performing gradient elution separation on the 3 rd fraction in the obtained 5 fractions by using a silica gel column chromatography to obtain 3 fractions, wherein the gradient eluent of the silica gel column chromatography comprises petroleum ether and ethyl acetate, and the volume ratio of the petroleum ether to the ethyl acetate is 4:1, 2:1 and 1: 1; and sixthly, purifying and separating the 3 rd fraction in the 3 obtained fractions by high performance liquid chromatography gradient elution, collecting the eluate, and obtaining 1,2,3,4,4a,9,10,10 a-octahydro-7-isoproyl-2, 4 a-dimethyl-1-methylenephenylenthrene-2, 9-diol (platelet D) at the 25.6 th minute.
In the first step, 8ml to 10ml of ethanol is added to every 1g of catalpa macrophylla.
In the sixth step, the eluent for gradient elution by high performance liquid chromatography is a mixed solution of methanol and water, wherein the volume ratio of methanol to water is 85: 15.
the second technical scheme of the invention is realized by the following measures: a method for preparing 1,2,3,4,4a,9,10,10a-octah hydro-7-isoproyl-2, 4 a-dimethyl-1-methyenepthalene-2, 9-diol (nepetabutyrate D) comprises the following steps: crushing the schizonepeta bracteata, adding ethanol, soaking for 3-4 hours at room temperature, heating and refluxing for 3 times at 50-60 ℃, extracting for 1-3 hours each time, combining the refluxing extracting solutions each time, and recovering and concentrating under reduced pressure to obtain a schizonepeta bracteatum total extract; secondly, dispersing the schizonepeta tenuifolia total extract by using water, and sequentially extracting by using petroleum ether and dichloromethane to obtain a petroleum ether part and a dichloromethane part; and step three, performing gradient elution and separation on the extract at the petroleum ether part by using a silica gel column chromatography to obtain 8 fractions, wherein the gradient eluent of the silica gel column chromatography comprises petroleum ether and ethyl acetate, and the volume ratio of the petroleum ether to the ethyl acetate is 1:0, 100:1 and 50: 1. 25:1, 8:1, 5:1, 1: 0; and fourthly, performing gradient elution separation on the 7 th fraction in the obtained 8 fractions by using a silica gel column chromatography to obtain 5 fractions, wherein the gradient eluent of the silica gel column chromatography comprises petroleum ether and ethyl acetate, and the volume ratio of the petroleum ether to the ethyl acetate is 15:1, 5:1 and 3: 1. 1:1, 0: 1; and fifthly, performing gradient elution separation on the 3 rd fraction in the obtained 5 fractions by using a silica gel column chromatography to obtain 3 fractions, wherein the gradient eluent of the silica gel column chromatography comprises petroleum ether and ethyl acetate, and the volume ratio of the petroleum ether to the ethyl acetate is 4:1, 2:1 and 1: 1; and sixthly, purifying and separating the 3 rd fraction in the 3 obtained fractions by high performance liquid chromatography gradient elution, collecting the eluate, and obtaining 1,2,3,4,4a,9,10,10 a-octahydro-7-isoproyl-2, 4a-dimethyl-1-methyl enephenyl anthrene-2,9-diol (beta-fumarate D) at the 25.6 th minute.
The following is further optimization or/and improvement of the second technical scheme of the invention:
in the first step, 8ml to 10ml of ethanol is added to every 1g of catalpa macrophylla.
In the sixth step, the eluent for gradient elution by high performance liquid chromatography is a mixed solution of methanol and water, wherein the volume ratio of methanol to water is 85: 15.
the third technical scheme of the invention is realized by the following measures: an application of 1,2,3,4,4a,9,10,10 a-octah-hydro-7-isoproyl-2, 4 a-dimethyl-1-methyenepthalene-2, 9-diol (nepetabutyrate D) in preparing the medicines for preventing inflammation and suppressing bacteria is disclosed.
The fourth technical scheme of the invention is realized by the following measures: an application of 1,2,3,4,4a,9,10,10 a-octah-hydro-7-isoproyl-2, 4 a-dimethyl-1-methyenephthalane-2, 9-diol (neobetabutyrate D) in preparing the medicines for anti-inflammation and antibacterial is disclosed.
The fifth technical scheme of the invention is realized by the following measures: an application of 1,2,3,4,4a,9,10,10 a-octah-hydro-7-isoproyl-2, 4 a-dimethyl-1-methyenepthalene-2, 9-diol (neoacetate D) in preparing the health-care products for preventing and treating inflammation and suppressing bacteria is disclosed.
The invention discloses a compound 1,2,3,4,4a,9,10,10 a-octahydro-7-isoproyl-2, 4 a-dimethyyl-1-methylenenaphthenanthrene-2, 9-diol (nebetafibrate D) for the first time, and the compound is subjected to in vitro anti-inflammatory and antibacterial pharmacodynamic experiments, and the experiments show that the compound has stronger inhibition effect on RAW 264.7 cells, staphylococcus aureus and escherichia coli, so that the compound can be used for preparing anti-inflammatory and antibacterial drugs or/and health-care products for preventing and treating inflammation and inhibiting bacteria.
Drawings
FIG. 1 is a chemical structural diagram of 1,2,3,4,4a,9,10,10 a-octahydro-7-isoproyl-2, 4 a-dimethyl-1-methyenephthalane-2, 9-diol (nepetabutyrate D) according to the present invention.
FIG. 2 shows 1,2,3,4,4a,9,10,10 a-octahydro-7-isoproyl-2, 4 a-dimethyl-1-methylenetetrahydrocene-2, 9-diol (nepetabutyrate D) according to the present invention1H-NMR spectrum.
FIG. 3 shows 1,2,3,4,4a,9,10,10 a-octahydro-7-isoproyl-2, 4 a-dimethyl-1-methylenetetrahydrocene-2, 9-diol (nepetabutyrate D) according to the present invention13C-APT spectrum.
Detailed Description
The present invention is not limited by the following examples, and specific embodiments may be determined according to the technical solutions and practical situations of the present invention. The various chemical reagents and chemical articles mentioned in the invention are all the chemical reagents and chemical articles which are well known and commonly used in the prior art, unless otherwise specified; the percentages in the invention are mass percentages unless otherwise specified; the solution in the present invention is an aqueous solution in which the solvent is water, for example, a hydrochloric acid solution is an aqueous hydrochloric acid solution, unless otherwise specified; the normal temperature and room temperature in the present invention generally mean a temperature of 15 ℃ to 25 ℃, and are generally defined as 25 ℃.
The invention is further described below with reference to the following examples:
example 1: the 1,2,3,4,4a,9,10,10 a-octahydro-7-isoproyl-2, 4 a-dimethyl-1-methyenetetrahydrocene-2, 9-diol (nepetabutyrate D) is characterized in that the chemical structural formula is shown as
Subjecting 1,2,3,4,4a,9,10,10 a-octahydro-7-isoproyl-2, 4 a-dimethyyl-1-methylenetetrahydrocene-2, 9-diol (nepetabutyrate D) described in example 1 of the present invention to nuclear magnetic resonance hydrogen spectroscopy (n)1H-NMR) and nuclear magnetic resonance carbon Spectroscopy (C13C-APT).
The 1,2,3,4,4a,9,10,10 a-octahydro-7-isoproyl-2, 4 a-dimethyl-1-m-ethylenenaphthene-2, 9-diol (nepetabutyrate D) described in this example1The H-NMR spectrum is shown in FIG. 2.
The 1,2,3,4,4a,9,10,10 a-octahydro-7-isoproyl-2, 4 a-dimethyl-1-methyenephthalane-2, 9-diol (nepetabutyrate D) described in this example13The C-APT spectrum is shown in FIG. 3.
The data in table 1 show that the chemical structural formula of 1,2,3,4,4a,9,10,10 a-octahydro-7-isoproyl-2, 4 a-dimethyl-1-methyenenaphthalene-2, 9-diol (terpene d) described in this example is shown in fig. 1, and is easily soluble in chloroform and methanol.
Example 2: the 1,2,3,4,4a,9,10,10 a-octahydro-7-isoproyl-2, 4a-dimethyl-1-methyl phenylenthrene-2, 9-diol (nepetabutyrate D) is prepared by the following method: crushing the schizonepeta bracteata, adding ethanol, soaking for 3-4 hours at room temperature, heating and refluxing for 3 times at 50-60 ℃, extracting for 1-3 hours each time, combining the refluxing extracting solutions each time, and recovering and concentrating under reduced pressure to obtain a schizonepeta bracteatum total extract; secondly, dispersing the schizonepeta tenuifolia total extract by using water, and sequentially extracting by using petroleum ether and dichloromethane to obtain a petroleum ether part and a dichloromethane part; and step three, performing gradient elution and separation on the extract at the petroleum ether part by using a silica gel column chromatography to obtain 8 fractions, wherein the gradient eluent of the silica gel column chromatography comprises petroleum ether and ethyl acetate, and the volume ratio of the petroleum ether to the ethyl acetate is 1:0, 100:1 and 50: 1. 25:1, 8:1, 5:1, 1: 0; and fourthly, performing gradient elution separation on the 7 th fraction in the obtained 8 fractions by using a silica gel column chromatography to obtain 5 fractions, wherein the gradient eluent of the silica gel column chromatography comprises petroleum ether and ethyl acetate, and the volume ratio of the petroleum ether to the ethyl acetate is 15:1, 5:1 and 3: 1. 1:1, 0: 1; and fifthly, performing gradient elution separation on the 3 rd fraction in the obtained 5 fractions by using a silica gel column chromatography to obtain 3 fractions, wherein the gradient eluent of the silica gel column chromatography comprises petroleum ether and ethyl acetate, and the volume ratio of the petroleum ether to the ethyl acetate is 4:1, 2:1 and 1: 1; and sixthly, purifying and separating the 3 rd fraction in the 3 obtained fractions by high performance liquid chromatography gradient elution, collecting the eluate, and obtaining 1,2,3,4,4a,9,10,10a-octa hydro-7-isoproyl-2, 4 a-dimethyl-1-methyenenaphthalene-2, 9-diol (platelet D) at the 25.6 th minute.
Example 3: as an optimization of the above embodiment, the 1,2,3,4,4a,9,10,10 a-octahydro-7-isoprop-2, 4 a-dimethyl-1-methylenetetrahydronaphthalene-2, 9-diol (nepetabutyrate D) can be prepared by the following method: crushing the schizonepeta bracteata, adding ethanol, soaking for 3 hours or 4 hours at room temperature, heating and refluxing for 3 times at 50 ℃ or 60 ℃ for 1 hour or 3 hours each time, combining the refluxing extracting solutions each time, and performing reduced pressure recovery and concentration to obtain a schizonepeta bracteatum total extract; secondly, dispersing the schizonepeta tenuifolia total extract by using water, and sequentially extracting by using petroleum ether and dichloromethane to obtain a petroleum ether part and a dichloromethane part; and step three, performing gradient elution and separation on the extract at the petroleum ether part by using a silica gel column chromatography to obtain 8 fractions, wherein the gradient eluent of the silica gel column chromatography comprises petroleum ether and ethyl acetate, and the volume ratio of the petroleum ether to the ethyl acetate is 1:0, 100:1 and 50: 1. 25:1, 8:1, 5:1, 1: 0; and fourthly, performing gradient elution separation on the 7 th fraction in the obtained 8 fractions by using a silica gel column chromatography to obtain 5 fractions, wherein the gradient eluent of the silica gel column chromatography comprises petroleum ether and ethyl acetate, and the volume ratio of the petroleum ether to the ethyl acetate is 15:1, 5:1 and 3: 1. 1:1, 0: 1; and fifthly, performing gradient elution separation on the 3 rd fraction in the obtained 5 fractions by using a silica gel column chromatography to obtain 3 fractions, wherein the gradient eluent of the silica gel column chromatography comprises petroleum ether and ethyl acetate, and the volume ratio of the petroleum ether to the ethyl acetate is 4:1, 2:1 and 1: 1; and sixthly, purifying and separating the 3 rd fraction in the 3 obtained fractions by high performance liquid chromatography gradient elution, collecting the eluate, and obtaining 1,2,3,4,4a,9,10,10 a-octahydro-7-isoproyl-2, 4 a-dimethyl-1-methylenetetrahydrocene-2, 9-diol (platelet D) at the 25.6 th minute.
Example 4: as an optimization of the above example, in the first step, 8ml to 10ml of ethanol was added per 1g of Nepeta cataria.
Example 5: as an optimization of the above embodiment, in the sixth step, the eluent for gradient elution by high performance liquid chromatography is a mixed solution of methanol and water, wherein the volume ratio of methanol to water is 85: 15.
example 6: the 1,2,3,4,4a,9,10,10 a-octahydro-7-isoproyl-2, 4 a-dimethyl-1-methyenetetrahydrocene-2, 9-diol (nepetabutyrate D) can be used for preparing medicines for preventing inflammation and inhibiting bacteria.
Example 7: the 1,2,3,4,4a,9,10,10 a-octahydro-7-isoproyl-2, 4 a-dimethyl-1-methyenetetrahydrocene-2, 9-diol (nepetabutyrate D) can be used for preparing anti-inflammatory and antibacterial medicaments.
Example 8: the 1,2,3,4,4a,9,10,10 a-octahydro-7-isoproyl-2, 4 a-dimethyl-1-methyenenaphthalene-2, 9-diol (nepetabutyrate D) is applied to the preparation of health products for preventing and treating inflammation and inhibiting bacteria.
Example 9: the 1,2,3,4,4a,9,10,10 a-octahydro-7-isoproyl-2, 4a-dimethyl-1-methyl phenylenthrene-2, 9-diol (nepetabutyrate D) is obtained by the following method: crushing the schizonepeta bracteata, adding ethanol, soaking for 3 hours at room temperature, heating and refluxing for 3 times and 2 hours each time at 50 ℃, combining reflux extracting solutions each time, and performing reduced pressure recovery and concentration to obtain a schizonepeta bracteatum total extract; secondly, dispersing the schizonepeta tenuifolia total extract by using water, and sequentially extracting by using petroleum ether and dichloromethane to obtain a petroleum ether part and a dichloromethane part; and step three, performing gradient elution and separation on the extract at the petroleum ether part by using a silica gel column chromatography to obtain 8 fractions, wherein the gradient eluent of the silica gel column chromatography comprises petroleum ether and ethyl acetate, and the volume ratio of the petroleum ether to the ethyl acetate is 1:0, 100:1 and 50: 1. 25:1, 8:1, 5:1, 1: 0; and fourthly, performing gradient elution separation on the 7 th fraction in the obtained 8 fractions by using a silica gel column chromatography to obtain 5 fractions, wherein the gradient eluent of the silica gel column chromatography comprises petroleum ether and ethyl acetate, and the volume ratio of the petroleum ether to the ethyl acetate is 15:1, 5:1 and 3: 1. 1:1, 0: 1; and fifthly, performing gradient elution separation on the 3 rd fraction in the obtained 5 fractions by using a silica gel column chromatography to obtain 3 fractions, wherein the gradient eluent of the silica gel column chromatography comprises petroleum ether and ethyl acetate, and the volume ratio of the petroleum ether to the ethyl acetate is 4:1, 2:1 and 1: 1; and sixthly, purifying and separating the 3 rd fraction in the 3 obtained fractions by high performance liquid chromatography gradient elution, collecting the eluate, and obtaining 1,2,3,4,4a,9,10,10 a-octahydro-7-isoproyl-2, 4 a-dimethyl-1-methylenetetrahydrocene-2, 9-diol (nepetabromide D) at the 25.6 th minute.
The 1,2,3,4,4a,9,10,10 a-octahydro-7-isoproyl-2, 4 a-dimethyyl-1-methyenephthalantrene-2, 9-diol (nepetabutyrate D) obtained in the example 9 of the invention is subjected to in vitro anti-inflammatory and antibacterial pharmacodynamic experiments, and the in vitro anti-inflammatory and antibacterial pharmacodynamic experiments utilize an MTT colorimetric method.
Taking 1,2,3,4,4a,9,10,10 a-octahydro-7-isoproyl-2, 4 a-dimethyl-1-methyenelene-2, 9-diol (nepetabutyrate D) as an experimental group, taking Aspirin (aspirin, an anti-inflammatory drug) as a control group, simultaneously setting a blank group, selecting RAW 264.7 cells as experimental objects in the experimental group, the control group and the blank group, diluting a culture medium, and then taking 6 x 104The density of each group is inoculated in a 96-well plate, each well is 100 mu l, after the group is normally cultured in an incubator for 24 hours, the corresponding drugs are added into each group, the final concentration of each group of drugs is respectively 2.5 mu g/ml (1 group), 5 mu g/ml (2 group), 10 mu g/ml (3 group), 20 mu g/ml (4 group) and 40 mu g/ml (5 group), 5 concentrations are set, and each concentration is 3 multiple wells; after 48 hours of incubation, 10. mu.l of MTT was added to each well for staining;continuously culturing for four hours, removing the stock culture solution, adding DMSO 150 μ l into each well, placing on a shaking table, shaking at low speed for 10min to dissolve the crystal completely, detecting optical density value at 570nm wavelength of enzyme-linked immunosorbent assay, and calculating 50% Inhibitory Concentration (IC) according to the optical density value50μ M), optical density value calculation IC50The calculation method of (2) is a prior known technology. IC of experiment group and control group on RAW 264.7 cell50As shown in table 2. As can be seen from the data in Table 2, the 1,2,3,4,4a,9,10,10 a-octahydro-7-isoproyl-2, 4 a-dimethyl-1-methyenepthalene-2, 9-diol (nepetabutyrate D) of the invention has a certain inhibitory effect on RAW 264.7 cells.
Taking 1,2,3,4,4a,9,10,10 a-octahydro-7-isoproyl-2, 4 a-dimethycin-1-methyephen antrene-2, 9-diol (nepetabutyrate D) as an experimental group, taking Penicillin (amoxicillin, antibacterial drug) as a control group, simultaneously setting a blank group, selecting staphylococcus aureus and escherichia coli as experimental objects in the experimental group, diluting a sample by sterile water or DMSO for a certain time, centrifuging to take 100 mu L of the sample, adding the sample into a hole of an indicator plate as an antibacterial experimental hole, taking a freshly cultured indicator strain, adjusting the concentration of a bacterial suspension to 0.5McFarland uniformly coating the indicator strain on the plate, placing the plate at a corresponding temperature for culturing for 24 hours or 48 hours, and observing the colony growth condition of each plate. 100 μ L of fresh medium was added to the wells as a negative control well and amoxicillin solution as a positive control. After dilution of the medium, the medium was diluted at 6X 104The density of each group is inoculated in a 96-well plate, each well is 100 mu l, after the group is normally cultured in an incubator for 24 hours, the corresponding drugs are added into each group, the final concentration of each group of drugs is respectively 2.5 mu g/ml (1 group), 5 mu g/ml (2 group), 10 mu g/ml (3 group), 20 mu g/ml (4 group) and 40 mu g/ml (5 group), 5 concentrations are set, and each concentration is 3 multiple wells; after 48 hours of incubation, 10. mu.l of MTT was added to each well for staining; continuously culturing for four hours, removing the stock culture solution, adding DMSO 150 μ l into each well, placing on a shaking table, shaking at low speed for 10min to dissolve the crystal completely, detecting optical density value at 570nm wavelength of enzyme-linked immunosorbent assay, and calculating 50% Inhibitory Concentration (IC) according to the optical density value50μ M), optical density value calculation IC50Is known in the artProvided is a technique. IC of experiment group, control group for staphylococcus aureus and escherichia coli50As shown in table 3. As can be seen from the data in Table 3, the 1,2,3,4,4a,9,10,10 a-octah-hydro-7-isoproyl-2, 4 a-dimethyl-1-methyenepthalene-2, 9-diol (heptabromate D) of the invention has certain inhibitory effect on both Staphylococcus aureus and Escherichia coli.
In conclusion, the invention discloses a compound 1,2,3,4,4a,9,10,10 a-octahydrophenyl-7-isoproyl-2, 4 a-dimethyl-1-methylenenaphthenanthrene-2, 9-diol (nebetafibrate D) for the first time, and the compound is subjected to in vitro anti-inflammatory and antibacterial pharmacodynamic experiments, and the experiments show that the compound has stronger inhibition effect on RAW 264.7 cells, staphylococcus aureus and escherichia coli, so that the compound can be used for preparing anti-inflammatory and antibacterial drugs or/and health-care products for preventing and treating inflammation and inhibiting bacteria.
The technical characteristics form an embodiment of the invention, which has strong adaptability and implementation effect, and unnecessary technical characteristics can be increased or decreased according to actual needs to meet the requirements of different situations.
TABLE 1
TABLE 2
TABLE 3
Claims (10)
1. 1,2,3,4,4a,9,10,10 a-octahydro-7-isoproyl-2, 4a-dimethyl-1-methyl ethylene-2, 9-diol (neopetanate D), characterized in that the chemical structural formula is
2. The 1,2,3,4,4a,9,10,10 a-octahydro-7-isoproyl-2, 4 a-dimethyl-1-methyenepthrene-2, 9-diol (nepetabutyrate D) according to claim 1, which is prepared by the following method: crushing the schizonepeta bracteata, adding ethanol, soaking for 3-4 hours at room temperature, heating and refluxing for 3 times at 50-60 ℃, extracting for 1-3 hours each time, combining the refluxing extracting solutions each time, and recovering and concentrating under reduced pressure to obtain a schizonepeta bracteatum total extract; secondly, dispersing the schizonepeta tenuifolia total extract by using water, and sequentially extracting by using petroleum ether and dichloromethane to obtain a petroleum ether part and a dichloromethane part; and step three, performing gradient elution and separation on the extract at the petroleum ether part by using a silica gel column chromatography to obtain 8 fractions, wherein the gradient eluent of the silica gel column chromatography comprises petroleum ether and ethyl acetate, and the volume ratio of the petroleum ether to the ethyl acetate is 1:0, 100:1 and 50: 1. 25:1, 8:1, 5:1, 1: 0; and fourthly, performing gradient elution separation on the 7 th fraction in the obtained 8 fractions by using a silica gel column chromatography to obtain 5 fractions, wherein the gradient eluent of the silica gel column chromatography comprises petroleum ether and ethyl acetate, and the volume ratio of the petroleum ether to the ethyl acetate is 15:1, 5:1 and 3: 1. 1:1, 0: 1; and fifthly, performing gradient elution separation on the 3 rd fraction in the obtained 5 fractions by using a silica gel column chromatography to obtain 3 fractions, wherein the gradient eluent of the silica gel column chromatography comprises petroleum ether and ethyl acetate, and the volume ratio of the petroleum ether to the ethyl acetate is 4:1, 2:1 and 1: 1; and sixthly, purifying and separating the 3 rd fraction in the 3 obtained fractions by high performance liquid chromatography gradient elution, collecting the eluate, and obtaining 1,2,3,4,4a,9,10,10 a-octahydro-7-isoproyl-2, 4 a-dimethyl-1-methylenetetrahydrocene-2, 9-diol (platelet D) at the 25.6 th minute.
3. The 1,2,3,4,4a,9,10,10 a-octahydro-7-isoproyl-2, 4 a-dimethyl-1-methyenepthrene-2, 9-diol (nepetafibrate d) according to claim 2, wherein in the first step 8ml to 10ml of ethanol is added per 1g of nepeta cataria.
4. The 1,2,3,4,4a,9,10,10 a-octahydro-7-isoproyl-2, 4 a-dimethyl-1-methylenenaphthacene-2, 9-diol (nepetabutyrate D) according to claim 2 or 3, wherein the eluent for gradient elution by high performance liquid chromatography is a mixed solution of methanol and water, wherein the volume ratio of methanol to water is 85: 15.
5. a method for preparing 1,2,3,4,4a,9,10,10 a-octahydro-7-isoproyl-2, 4 a-dimethyl-1-methylenetetrahydronaphthalene-2, 9-diol (nepetabutyrate d) according to claim 1, comprising the steps of: crushing the schizonepeta bracteata, adding ethanol, soaking for 3-4 hours at room temperature, heating and refluxing for 3 times at 50-60 ℃, extracting for 1-3 hours each time, combining the refluxing extracting solutions each time, and recovering and concentrating under reduced pressure to obtain a schizonepeta bracteatum total extract; secondly, dispersing the schizonepeta tenuifolia total extract by using water, and sequentially extracting by using petroleum ether and dichloromethane to obtain a petroleum ether part and a dichloromethane part; and step three, performing gradient elution and separation on the extract at the petroleum ether part by using a silica gel column chromatography to obtain 8 fractions, wherein the gradient eluent of the silica gel column chromatography comprises petroleum ether and ethyl acetate, and the volume ratio of the petroleum ether to the ethyl acetate is 1:0, 100:1 and 50: 1. 25:1, 8:1, 5:1, 1: 0; and fourthly, performing gradient elution separation on the 7 th fraction in the obtained 8 fractions by using a silica gel column chromatography to obtain 5 fractions, wherein the gradient eluent of the silica gel column chromatography comprises petroleum ether and ethyl acetate, and the volume ratio of the petroleum ether to the ethyl acetate is 15:1, 5:1 and 3: 1. 1:1, 0: 1; and fifthly, performing gradient elution separation on the 3 rd fraction in the obtained 5 fractions by using a silica gel column chromatography to obtain 3 fractions, wherein the gradient eluent of the silica gel column chromatography comprises petroleum ether and ethyl acetate, and the volume ratio of the petroleum ether to the ethyl acetate is 4:1, 2:1 and 1: 1; and sixthly, purifying and separating the 3 rd fraction in the 3 obtained fractions by high performance liquid chromatography gradient elution, collecting the eluate, and obtaining 1,2,3,4,4a,9,10,10 a-octahydro-7-isoproyl-2, 4 a-dimethyl-1-methylenetetrahydrocene-2, 9-diol (platelet D) at the 25.6 th minute.
6. The method for producing 1,2,3,4,4a,9,10,10 a-octahydro-7-isoproyl-2, 4 a-dimethyl-1-methyenepthrene-2, 9-diol (nepetafibrate D) according to claim 5, wherein in the first step, 8ml to 10ml of ethanol is added per 1g of nepeta cataria.
7. The method for preparing 1,2,3,4,4a,9,10,10 a-octahydro-7-isoproyl-2, 4 a-dimethyl-1-methylenetetrahydrocene-2, 9-diol (nepetabutyrate D) according to claim 5 or 6, wherein the eluent for gradient elution by HPLC is a mixture of methanol and water, wherein the volume ratio of methanol to water is 85: 15.
8. use of 1,2,3,4,4a,9,10,10a-octahydro-7-is oppyl-2, 4 a-dimethyl-1-methyenepthrene-2, 9-diol (nepetabutyrate D) according to claim 1,2,3 or 4 for the preparation of a medicament for preventing inflammation and inhibiting bacteria.
9. Use of 1,2,3,4,4a,9,10,10a-octahydro-7-is oppyl-2, 4 a-dimethyl-1-methyenepthrene-2, 9-diol (nepetafibrate D) according to claim 1,2,3 or 4 for the preparation of anti-inflammatory and antibacterial medicaments.
10. The use of 1,2,3,4,4a,9,10,10a-octahydro-7-is oppyl-2, 4 a-dimethyl-1-methyenepthrene-2, 9-diol (pentahydrate D) according to claim 1,2,3 or 4 for the preparation of a health product for preventing and treating inflammation and inhibiting bacteria.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111050049.4A CN114044734B (en) | 2021-09-08 | 2021-09-08 | Rosin alkane diterpene and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111050049.4A CN114044734B (en) | 2021-09-08 | 2021-09-08 | Rosin alkane diterpene and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114044734A true CN114044734A (en) | 2022-02-15 |
| CN114044734B CN114044734B (en) | 2023-08-29 |
Family
ID=80204364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111050049.4A Active CN114044734B (en) | 2021-09-08 | 2021-09-08 | Rosin alkane diterpene and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114044734B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114890870A (en) * | 2022-06-07 | 2022-08-12 | 新疆维吾尔自治区中药民族药研究所 | Abietane diterpene in schizonepeta bracteata extract as well as preparation method and application thereof |
| CN115010589A (en) * | 2022-06-07 | 2022-09-06 | 新疆维吾尔自治区中药民族药研究所 | Botrytis serrata bract abietane diterpenoid component in hyssop officinalis extract and preparation method and application thereof |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050234260A1 (en) * | 2004-04-20 | 2005-10-20 | Chi-Ming Che | Supported ruthenium nanoparticle catalyst for cis -dihydroxylation and oxidative cleavage of alkenes |
| CN102295545A (en) * | 2010-06-23 | 2011-12-28 | 中国科学院大连化学物理研究所 | Method for biosynthesizing abietane diterpenoid compounds by using cephalotaxus fortune culture cells |
| CN103224616A (en) * | 2012-01-26 | 2013-07-31 | 施乐公司 | Synthesis of abietic acid-based macromer for polyester resin process |
| CN105837592A (en) * | 2015-01-11 | 2016-08-10 | 复旦大学 | Phloroglucinolo abietane diterpenoid compound, preparation method thereof and medicinal application |
| CN107746403A (en) * | 2017-06-26 | 2018-03-02 | 中国科学院昆明植物研究所 | Serial open loop Diterpene class compound and its pharmaceutical composition and its application in pharmacy |
| CN108129295A (en) * | 2018-01-12 | 2018-06-08 | 云南大学 | A kind of Diterpene derivative and its pharmaceutical composition and purposes |
| TWI648253B (en) * | 2017-11-10 | 2019-01-21 | 義守大學 | Method of purifying kirenol |
| CN110840867A (en) * | 2019-11-14 | 2020-02-28 | 中国科学院昆明植物研究所 | Application of abietane diterpenoid compound in preparation of medicine for preventing and/or treating thrombotic diseases |
-
2021
- 2021-09-08 CN CN202111050049.4A patent/CN114044734B/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050234260A1 (en) * | 2004-04-20 | 2005-10-20 | Chi-Ming Che | Supported ruthenium nanoparticle catalyst for cis -dihydroxylation and oxidative cleavage of alkenes |
| CN102295545A (en) * | 2010-06-23 | 2011-12-28 | 中国科学院大连化学物理研究所 | Method for biosynthesizing abietane diterpenoid compounds by using cephalotaxus fortune culture cells |
| CN103224616A (en) * | 2012-01-26 | 2013-07-31 | 施乐公司 | Synthesis of abietic acid-based macromer for polyester resin process |
| CN105837592A (en) * | 2015-01-11 | 2016-08-10 | 复旦大学 | Phloroglucinolo abietane diterpenoid compound, preparation method thereof and medicinal application |
| CN107746403A (en) * | 2017-06-26 | 2018-03-02 | 中国科学院昆明植物研究所 | Serial open loop Diterpene class compound and its pharmaceutical composition and its application in pharmacy |
| TWI648253B (en) * | 2017-11-10 | 2019-01-21 | 義守大學 | Method of purifying kirenol |
| CN108129295A (en) * | 2018-01-12 | 2018-06-08 | 云南大学 | A kind of Diterpene derivative and its pharmaceutical composition and purposes |
| CN110840867A (en) * | 2019-11-14 | 2020-02-28 | 中国科学院昆明植物研究所 | Application of abietane diterpenoid compound in preparation of medicine for preventing and/or treating thrombotic diseases |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114890870A (en) * | 2022-06-07 | 2022-08-12 | 新疆维吾尔自治区中药民族药研究所 | Abietane diterpene in schizonepeta bracteata extract as well as preparation method and application thereof |
| CN115010589A (en) * | 2022-06-07 | 2022-09-06 | 新疆维吾尔自治区中药民族药研究所 | Botrytis serrata bract abietane diterpenoid component in hyssop officinalis extract and preparation method and application thereof |
| CN115010589B (en) * | 2022-06-07 | 2024-03-12 | 新疆维吾尔自治区中药民族药研究所 | Large bud abietane diterpenoid component in vanilla extract, and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114044734B (en) | 2023-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113861008B (en) | Large bud rosin diterpene, preparation method thereof and application thereof in preparation of anti-inflammatory and antibacterial drugs for preventing or/and treating inflammation | |
| CN113831245B (en) | Diterpene in schizonepeta tenuifolia extract, and preparation method and application thereof | |
| CN114044734A (en) | Abietane diterpene and preparation method and application thereof | |
| CN108503521B (en) | Guaiane type sesquiterpene A, its preparation method and application in preparing medicine for preventing tumor and resisting tumor | |
| CN113861126B (en) | Highly oxidized diterpene, preparation method thereof and application thereof in preparation of anti-inflammatory and antibacterial drugs for preventing or/and treating inflammation | |
| CN113943211B (en) | Diterpene in Uighur medicinal material, preparation method thereof and application of diterpene in preparation of anti-inflammatory and antibacterial medicines for preventing or/and treating inflammation | |
| CN116354917A (en) | Dendrobium aureosallowii endophytic fungus chromone compound DWT001 and preparation and application thereof | |
| CN113861208B (en) | Cytochalasin compound and preparation method and application thereof | |
| CN114890870A (en) | Abietane diterpene in schizonepeta bracteata extract as well as preparation method and application thereof | |
| CN109369399B (en) | 1, 3-O-diferulate-2-methoxy propylene glycol and preparation method and application thereof | |
| CN114933602A (en) | High-oxidation germacrane type sesquiterpene lactone compounds in elephantopus scaber and preparation method and application thereof | |
| CN111253352B (en) | Compound extracted and separated from traditional Chinese medicine cymbidium maculatum, and preparation method and application thereof | |
| CN109651233B (en) | Alkaloid compound, and method for extracting and separating alkaloid compound from dendrobium clavatum and application of alkaloid compound | |
| CN112125918B (en) | Aromatic polyketone compounds Talarogyoxanones A and B as well as preparation method and application thereof | |
| CN114853610A (en) | Preparation method and application of abietane diterpene in schizonepeta bracteata | |
| CN108299178B (en) | Guaiane type sesquiterpene B, preparation method thereof and application of guaiane type sesquiterpene B in preparation of tumor prevention and antitumor drugs | |
| CN114805030B (en) | Diterpenoid component in schizonepeta tenuifolia extract, and preparation method and application thereof | |
| CN115286673B (en) | Sesquiterpenoids derived from calix sponge, and extraction method and application thereof | |
| CN115010589B (en) | Large bud abietane diterpenoid component in vanilla extract, and preparation method and application thereof | |
| CN116003238B (en) | Sesquiterpenoids in jasmine roots, and extraction method and application thereof | |
| CN115073413B (en) | Benzocyclic ether sesquiterpenes compound and preparation method and application thereof | |
| CN115043719B (en) | Polyketide from fungus, preparation method and application thereof | |
| CN108774115B (en) | Diterpenoid-reducing compound, separation method thereof and application of diterpenoid-reducing compound in neuraminidase resistance | |
| CN114957273B (en) | New xanthenone compounds with inhibitory activity on quorum sensing effect in 4 kinds of hypericum curvatum, and separation and purification method and application thereof | |
| CN113248382B (en) | Antioxidant compound and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |